Is Cleo Diagnostics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Cleo Diagnostics Ltd (COV.AX) is currently classified as NOT HALAL as of April 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Cleo Diagnostics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cleo Diagnostics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Cleo Diagnostics Ltd?

Muslim investors may consider investing in Cleo Diagnostics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cleo Diagnostics Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Cleo Diagnostics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cleo Diagnostics Ltd updated?

The Shariah compliance status of Cleo Diagnostics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cleo Diagnostics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cleo Diagnostics Ltd?

You can check the latest Shariah compliance status of Cleo Diagnostics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

COV.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 17, 2025

Report Source: 2025 2nd Quarter Report

Cleo Diagnostics Ltd. Stock Analysis COV.AX

Australia Health Care Micro Cap Report: Q2, 2025

CLEO Diagnostics Ltd. is a medical diagnostics/devices company which mainly focuses on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company is headquartered in Melbourne, Victoria. The company went IPO on 2023-08-22. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. The company focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is absent in non-malignant disease. The company is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. Triage Test is a pre-surgical test to determine ovarian or adnexal mass for which surgical referral is required who have not yet been referred to an oncologist.

Key Statistics of Cleo Diagnostics Ltd (COV.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.66AUD0.70

Today's Open

AUD0.67

Volume

357.42K

P/E Ratio (TTM)

52 Week Range

AUD0.32AUD0.90

Market Cap

82.80M

Avg. Volume

17.66K

Dividend Yield

Financial Metrics & Statements of Cleo Diagnostics Ltd (COV.AX)

FAQ's for Cleo Diagnostics Ltd (COV.AX)

According to Musaffa’s Shariah screening methodology, Cleo Diagnostics Ltd (COV.AX) is currently classified as NOT HALAL as of April 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.